Introduction: We investigated the differences between prostate cancer patients with radiation-induced hematuria treated with hyperbaric oxygen (HBO) therapy that did or did not have a resolution of hematuria. Materials and Methods: We performed a retrospective review of prostate cancer patients with radiation-induced hematuria who underwent HBO from April 2000 to March 2010. We performed an analysis of demographic data and severity of hematuria in those who had resolution of or persistent hematuria. Additionally, prostate-specific antigen (PSA) data were also obtained during the study period. Results: Overall, 11/22 men had resolution of hematuria after HBO therapy with a median follow-up of 2.2 (0.35-13.6) years. The Radiation Therapy Oncology Group (RTOG) grade of hematuria is predictive of final hematuria outcome (resolution vs. persistent) after HBO (p = 0.026). No significant PSA changes were noted before and after HBO therapy. Conclusions: The RTOG hematuria grade is associated with the resolution of hematuria after HBO therapy for radiation-induced hematuria in men treated for prostate cancer. This information may be helpful during shared medical decision-making regarding utility of HBO therapy in the context of severity of hematuria.

Keywords:
Hyperbaric oxygen, Radiation cystitis, Hematuria, Prostate-specific antigen
1.
Jereczek-Fossa BA, Orecchia R: Evidence-based radiation oncology: definitive, adjuvant and salvage radiotherapy for non-metastatic prostate cancer. Radiother Oncol 2007;84:197-215.
2.
Crew JP, Jephcott CR, Reynard JM: Radiation-induced haemorrhagic cystitis. Eur Urol 2001;40:111-123.
3.
Levenback C, Eifel PJ, Burke TW, Morris M, Gershenson DM: Hemorrhagic cystitis following radiotherapy for stage Ib cancer of the cervix. Gynecol Oncol 1994;55:206-210.
4.
Greskovich FJ, Zagars GK, Sherman NE, Johnson DE: Complications following external beam radiation therapy for prostate cancer: an analysis of patients treated with and without staging pelvic lymphadenectomy. J Urol 1991;146:798-802.
5.
Moreno JG, Ahlering TE: Late local complications after definitive radiotherapy for prostatic adenocarcinoma. J Urol 1992;147:926-928.
6.
Lawton CA, Won M, Pilepich MV, Asbell SO, Shipley WU, Hanks GE, Cox JD, Perez CA, Sause WT, Doggett SR, et al: Long-term treatment sequelae following external beam irradiation for adenocarcinoma of the prostate: analysis of RTOG studies 7506 and 7706. Int J Radiat Oncol Biol Phys 1991;21:935-939.
7.
Bevers RF, Bakker DJ, Kurth KH: Hyperbaric oxygen treatment for haemorrhagic radiation cystitis. Lancet 1995;346:803-805.
8.
Corman JM, McClure D, Pritchett R, Kozlowski P, Hampson NB: Treatment of radiation induced hemorrhagic cystitis with hyperbaric oxygen. J Urol 2003;169:2200-2202.
9.
Mohamad Al-Ali B, Trummer H, Shamloul R, Zigeuner R, Pummer K: Is treatment of hemorrhagic radiation cystitis with hyperbaric oxygen effective? Urol Int 2010;84:467-470.
10.
Norkool DM, Hampson NB, Gibbons RP, Weissman RM: Hyperbaric oxygen therapy for radiation-induced hemorrhagic cystitis. J Urol 1993;150:332-334.
11.
Feldmeier JJ, Heimbach RD, Davolt DA, Brakora MJ, Sheffield PJ, Porter AT: Does hyperbaric oxygen have a cancer-causing or -promoting effect? A review of the pertinent literature. Undersea Hyperb Med 1994;21:467-475.
12.
Roach M 3rd, Hanks G, Thames H Jr, Schellhammer P, Shipley WU, Sokol GH, Sandler H: Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 2006;65:965-974.
13.
Wessells H, McAninch JW: Urological Emergencies: A Practical Guide. Totowa, Humana Press, 2005.
14.
Hwang C, Heath EI: Angiogenesis inhibitors in the treatment of prostate cancer. J Hematol Oncol 2010;3:26.
15.
Vilar DG, Fadrique GG, Martin IJ, Aguado JM, Perello CG, Argente VG, Sanz MB, Gomez JG: Hyperbaric oxygen therapy for the management of hemorrhagic radio-induced cystitis. Arch Esp Urol 2011;64:869-874.
16.
Mathews R, Rajan N, Josefson L, Camporesi E, Makhuli Z: Hyperbaric oxygen therapy for radiation induced hemorrhagic cystitis. J Urol 1999;161:435-437.
17.
Kalns JE, Piepmeier EH: Exposure to hyperbaric oxygen induces cell cycle perturbation in prostate cancer cells. In Vitro Cell Dev Biol Anim 1999;35:98-101.
18.
Chong KT, Hampson NB, Bostwick DG, Vessella RL, Corman JM: Hyperbaric oxygen does not accelerate latent in vivo prostate cancer: implications for the treatment of radiation-induced haemorrhagic cystitis. BJU Int 2004;94:1275-1278.
19.
Tang H, Zhang ZY, Ge JP, Zhou WQ, Gao JP: Effects of hyperbaric oxygen on tumor growth in the mouse model of lncap prostate cancer cell line (in Chinese). Zhonghua Nan Ke Xue 2009;15:713-716.
20.
Daruwalla J, Christophi C: Hyperbaric oxygen therapy for malignancy: a review. World J Surg 2006;30:2112-2131.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.